Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorization of MabThera (rituximab) for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphoc…
-
EMA approval · 2026-08-06EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) by Roche Registration GmbH for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis…
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL [Phase 2]
A phase 2 pilot study evaluating metformin therapy in patients with relapsed and untreated chronic lymphocytic leukemia.
-
EMA approval · 2026-07-10EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA confirms authorisation of Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias; product is authorised fo…
-
EMA approval · 2026-07-08EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias, broadening its approved therapeutic use…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-06EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB
AstraZeneca's Calquence (acalabrutinib, acalabrutinib maleate) has been authorised by EMA for chronic lymphocytic leukemia and related B-cel…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) [Phase 3]
Phase III study evaluating Panzyga for primary infection prophylaxis in chronic lymphocytic leukemia with hypogammaglobulinemia has complete…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
NCI-sponsored clinical trial update describes collecting human samples to study hairy cell leukemia and other leukemias, and to develop reco…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
An NCI-sponsored trial characterizes individuals and families at high risk of hematologic cancers, focusing on conditions including Waldenst…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
This clinical trial entry describes a study to establish a tumor bank in families with multiple lymphoproliferative malignancies and is curr…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Understanding Chronic Lymphocytic Leukemia
This clinical trial update indicates that the study investigating treatments for Chronic Lymphocytic Leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia [EARLY_Phase 1]
A Phase 1 clinical trial evaluating the safety and efficacy of GT801 Injection in adults with relapsed/refractory CD19-positive B-cell hemat…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) [Phase 3]
A Phase 3 study CELESTIAL-RRCLL is evaluating progression-free survival with Sonrotoclax in combination with Obinutuzumab or Rituximab, vers…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
An observational study evaluating acalabrutinib in patients with chronic lymphocytic leukemia in the United Kingdom is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Acalabrutinib Real World Italian obSErvational Study -ARISE
An active, non-recruiting real-world observational study in Italy evaluating acalabrutinib for chronic lymphocytic leukemia (ARISE), sponsor…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial is investigating the combination of Sonrotoclax with Zanubrutinib versus Zanubrutinib alone in previously untreated…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 trial evaluating Sonrotoclax plus Zanubrutinib versus Venetoclax plus Acalabrutinib in adults with previously untreated chronic ly…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
This clinical trial update describes a Phase 3 study comparing the safety and efficacy of BGB-16673 versus Pirtobrutinib in adults with rela…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors [Phase 3]
A Phase 3 clinical trial comparing BGB-16673 to investigator's choice in chronic lymphocytic leukemia or small lymphocytic lymphoma patients…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study of a triple therapy (Sonrotoclax, Rituximab, and Zanubrutinib) for chronic lymphocytic …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study [Phase 3]
The EVOLVE CLL/SLL study is a Phase 3 clinical trial sponsored by the National Cancer Institute to evaluate early treatment in patients with…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors [Phase 3]
A Phase 3 study evaluating BGB-16673 versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic l…
-
CLINICAL_TRIALS other · 2026-04-22Clinical Trial Update: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) [Phase 3]
This Phase 3 trial update describes a study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) versus Venetoclax plus Obinutuzumab in c…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
This clinical trial update describes a study investigating determinants of response to BTK degraders in chronic lymphocytic leukemia, curren…